-
1
المؤلفون: Stephen E Gitelman, Brian N Bundy, Ele Ferrannini, Noha Lim, J Lori Blanchfield, Linda A DiMeglio, Eric I Felner, Jason L Gaglia, Peter A Gottlieb, S Alice Long, Andrea Mari, Raghavendra G Mirmira, Philip Raskin, Srinath Sanda, Eva Tsalikian, John M Wentworth, Steven M Willi, Jeffrey P Krischer, Jeffrey A Bluestone, Mayalin Barr, Jeanne Buchanan, Joanne Cabbage, Peter Coleman, Monica De La Vega, Carmella Evans-Molina, Christine Ferrara, Felicity Healy, Laurie Higgins, Megan Hildinger, Margaret Jenkins, Nora Kayton Bryant, Amanda Kinderman, Nisha Koshy, Brianne Kost, Suzanne Krishfield, Olena Kucheruk, Karen Lindsley, Manasa Mantravadi, Shelley Mesfin, Aaron Michels, Mary Ellen Migre, Pantea Minnock, Elham Mohammed-Nur, Jennifer Nelson, Ashvin Nursing, Ryan O'Donnell, Diana Olivos, Melissa Parker, Leanne Redl, Nicole Reed, Brittany Resnick, Peter Sayre, Elisavet Serti, Emily Sims, Karen Smith, Carol Soppe, Fiona Stuart, Sarah Szubowicz, Michel Tansey, Jennifer Terrell, Sarah Tersey, Christine Torok, Kelly Watson, Rebecca Wesch, Steven Willi, Stephanie Woerner
المصدر: Lancet Diabetes Endocrinol
مصطلحات موضوعية: Adult, Blood Glucose, Male, medicine.medical_specialty, Adolescent, Endocrinology, Diabetes and Metabolism, Population, 030209 endocrinology & metabolism, Placebo, Article, law.invention, 03 medical and health sciences, Young Adult, 0302 clinical medicine, Endocrinology, Randomized controlled trial, Double-Blind Method, law, Internal medicine, Internal Medicine, Clinical endpoint, Medicine, Humans, 030212 general & internal medicine, education, Adverse effect, Protein Kinase Inhibitors, Type 1 diabetes, education.field_of_study, business.industry, Middle Aged, medicine.disease, Prognosis, Discontinuation, Clinical trial, Diabetes Mellitus, Type 1, Imatinib Mesylate, Female, business, Biomarkers, Follow-Up Studies